Oxazolidinones as .alpha..sub.1A receptor antagonists

US6159990A · kind A · utility

Assignee

• Synaptic Pharmaceutical Corporation · US

Inventors

• Bharat Lagu · Maywood, US
• T.G. Murali Dhar · Carbondale, US
• Dhanapalan Nagarathnam · Bethany, US
• Yoon Jeon · Montgomery, US
• Mohammad R. Marzabadi · Ridgewood, US
• Wai C. Wong · Newark, US
• Charles Gluchowski · Mission Viejo, US

Key dates

• Filing date: Jun 17, 1998
• Grant date: Dec 12, 2000
• Expiry date: Jun 17, 2018

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention is directed to oxazolidinone compounds which are selective antagonists for human .alpha..sub.1A receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where the antagonism of the .alpha..sub.1A receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.